POTE ankyrin domain family member CGenealiases: A26B2 · CT104.6 · POTE-18 · POTE18
Q-omics provides the consensus-scored POTEC profile across patient tissues and cancer cell-line models. POTEC expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, POTEC is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, POTEC RNA expression shows 9,672 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, BRCA, and UVM as cancer lineages where POTEC shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POTEC — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POTEC survival associations across molecular data types. POTEC RNA expression shows survival associations in the most cancer types (15), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POTEC RNA expression–survival associations across cancer types. High POTEC expression shows unfavorable associations in ACC, UVM, KIRC and MESO, but favorable associations in READ and UCS. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify ACC as the clearest survival context for POTEC RNA expression.
This table summarizes POTEC tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for POTEC. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POTEC shows higher tumor expression in BRCA, LUSC, PRAD, LIHC and HNSC. The BRCA box plot shows higher POTEC RNA expression in tumor versus normal tissue (log2 FC = +0.347, t-test p < 0.001).
This table shows molecular features associated with POTEC in patient tissues and cancer cell lines. In patient samples, POTEC shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, POTEC RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
